APO Research
Talk to an analyst

APO RESEARCH · REPORT

Transmucosal Drug Delivery

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Transmucosal Drug Delivery Market Outlook and Growth Opportunities 2026

22 December 2025214 pages

Choose your research edition.

Industry ResearchTransmucosal Drug Delivery Industry Research Report 2026142 pages · $2,950 USDIndustry Growth & TrendsGlobal Transmucosal Drug Delivery Industry Growth and Trends Forecast to 2032124 pages · $3,450 USDMarket StructureGlobal Transmucosal Drug Delivery Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Transmucosal Drug Delivery Market Outlook and Growth Opportunities 2026214 pages · $4,250 USDMarket Analysis & ForecastGlobal Transmucosal Drug Delivery Market Analysis and Forecast 2026-2032214 pages · $4,950 USD

Market perspective

The global Transmucosal Drug Delivery market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Transmucosal Drug Delivery is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Transmucosal Drug Delivery is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Transmucosal Drug Delivery is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Transmucosal Drug Delivery market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Transmucosal Drug Delivery market include TEVA Pharmaceutical Industries Ltd., Mylan, Inc., Zosano Pharma, tesa Labtec GmbH, Tapemark, Pantec Biosolutions AG, Noven Pharmaceuticals, Inc., Nitto Denko Corporation and Nemaura Pharma Ltd, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global Transmucosal Drug Delivery market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Transmucosal Drug Delivery and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Transmucosal Drug Delivery revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global Transmucosal Drug Delivery market.

Transmucosal Drug Delivery Segment by Company

TEVA Pharmaceutical Industries Ltd.

Mylan, Inc.

Zosano Pharma

tesa Labtec GmbH

Tapemark

Pantec Biosolutions AG

Noven Pharmaceuticals, Inc.

Nitto Denko Corporation

Nemaura Pharma Ltd

MedPharm LTD

Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)

Inovio Pharmaceuticals, Inc.

Generex Biotechnology Corporation

DURECT Corporation

Corium International, Inc

Aveva Drug Delivery Systems

Apricus BioSciences, Inc

Antares Pharma, Inc.

ALZA Corporation

Acrux Limited

3M Pharmaceuticals

Transmucosal Drug Delivery Segment by Type

Passive Transdermal Drug Delivery

Active Transdermal Drug Delivery

Transmucosal Drug Delivery Segment by Application

Hospital

Clinic

Others

Transmucosal Drug Delivery Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Transmucosal Drug Delivery status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the Transmucosal Drug Delivery key companies, revenue, market share, and recent developments.

3. To split the Transmucosal Drug Delivery breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions Transmucosal Drug Delivery market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Transmucosal Drug Delivery significant trends, drivers, influence factors in global and regions.

6. To analyze Transmucosal Drug Delivery competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Transmucosal Drug Delivery market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Transmucosal Drug Delivery and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Transmucosal Drug Delivery.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Transmucosal Drug Delivery industry.

Chapter 3: Detailed analysis of Transmucosal Drug Delivery company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of Transmucosal Drug Delivery in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of Transmucosal Drug Delivery in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Transmucosal Drug Delivery Industry Trends Table 2. Transmucosal Drug Delivery Industry Drivers Table 3. Transmucosal Drug Delivery Industry Opportunities and Challenges Table 4. Transmucosal Drug Delivery Industry Restraints Table 5. Global Transmucosal Drug Delivery Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Transmucosal Drug Delivery Revenue Share by Company (2021-2026) Table 7. Global Transmucosal Drug Delivery Company Ranking, (2024-2026) & (US$ Million) Table 8. Global Transmucosal Drug Delivery Key Company Manufacturing Base & Headquarters Table 9. Global Transmucosal Drug Delivery Company, Product Type & Application Table 10. Global Transmucosal Drug Delivery Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global Transmucosal Drug Delivery by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of Passive Transdermal Drug Delivery Table 15. Significant Companies of Active Transdermal Drug Delivery Table 16. Global Transmucosal Drug Delivery Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 17. Global Transmucosal Drug Delivery Sales Value by Type (2021-2026) & (US$ Million) Table 18. Global Transmucosal Drug Delivery Sales Value by Type (2027-2032) & (US$ Million) Table 19. Global Transmucosal Drug Delivery Sales Value Share by Type (2021-2026) Table 20. Global Transmucosal Drug Delivery Sales Value Share by Type (2027-2032) Table 21. Significant Companies of Hospital Table 22. Significant Companies of Clinic Table 23. Significant Companies of Others Table 24. Global Transmucosal Drug Delivery Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Transmucosal Drug Delivery Sales Value by Application (2021-2026) & (US$ Million) Table 26. Global Transmucosal Drug Delivery Sales Value by Application (2027-2032) & (US$ Million) Table 27. Global Transmucosal Drug Delivery Sales Value Share by Application (2021-2026) Table 28. Global Transmucosal Drug Delivery Sales Value Share by Application (2027-2032) Table 29. Global Transmucosal Drug Delivery Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 30. Global Transmucosal Drug Delivery Sales Value by Region (2021-2026) & (US$ Million) Table 31. Global Transmucosal Drug Delivery Sales Value Share by Region (2021-2026) Table 32. Global Transmucosal Drug Delivery Sales Value by Region (2027-2032) & (US$ Million) Table 33. Global Transmucosal Drug Delivery Sales Value Share by Region (2027-2032) Table 34. Global Transmucosal Drug Delivery Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 35. Global Transmucosal Drug Delivery Sales Value by Country (2021-2026) & (US$ Million) Table 36. Global Transmucosal Drug Delivery Sales Value Market Share by Country (2021-2026) Table 37. Global Transmucosal Drug Delivery Sales Value by Country (2027-2032) & (US$ Million) Table 38. Global Transmucosal Drug Delivery Sales Value Market Share by Country (2027-2032) Table 39. TEVA Pharmaceutical Industries Ltd. Company Information Table 40. TEVA Pharmaceutical Industries Ltd. Business Overview Table 41. TEVA Pharmaceutical Industries Ltd. Transmucosal Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 42. TEVA Pharmaceutical Industries Ltd. Transmucosal Drug Delivery Product Portfolio Table 43. TEVA Pharmaceutical Industries Ltd. Recent Development Table 44. Mylan, Inc. Company Information Table 45. Mylan, Inc. Business Overview Table 46. Mylan, Inc. Transmucosal Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 47. Mylan, Inc. Transmucosal Drug Delivery Product Portfolio Table 48. Mylan, Inc. Recent Development Table 49. Zosano Pharma Company Information Table 50. Zosano Pharma Business Overview Table 51. Zosano Pharma Transmucosal Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 52. Zosano Pharma Transmucosal Drug Delivery Product Portfolio Table 53. Zosano Pharma Recent Development Table 54. tesa Labtec GmbH Company Information Table 55. tesa Labtec GmbH Business Overview Table 56. tesa Labtec GmbH Transmucosal Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 57. tesa Labtec GmbH Transmucosal Drug Delivery Product Portfolio Table 58. tesa Labtec GmbH Recent Development Table 59. Tapemark Company Information Table 60. Tapemark Business Overview Table 61. Tapemark Transmucosal Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 62. Tapemark Transmucosal Drug Delivery Product Portfolio Table 63. Tapemark Recent Development Table 64. Pantec Biosolutions AG Company Information Table 65. Pantec Biosolutions AG Business Overview Table 66. Pantec Biosolutions AG Transmucosal Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 67. Pantec Biosolutions AG Transmucosal Drug Delivery Product Portfolio Table 68. Pantec Biosolutions AG Recent Development Table 69. Noven Pharmaceuticals, Inc. Company Information Table 70. Noven Pharmaceuticals, Inc. Business Overview Table 71. Noven Pharmaceuticals, Inc. Transmucosal Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 72. Noven Pharmaceuticals, Inc. Transmucosal Drug Delivery Product Portfolio Table 73. Noven Pharmaceuticals, Inc. Recent Development Table 74. Nitto Denko Corporation Company Information Table 75. Nitto Denko Corporation Business Overview Table 76. Nitto Denko Corporation Transmucosal Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 77. Nitto Denko Corporation Transmucosal Drug Delivery Product Portfolio Table 78. Nitto Denko Corporation Recent Development Table 79. Nemaura Pharma Ltd Company Information Table 80. Nemaura Pharma Ltd Business Overview Table 81. Nemaura Pharma Ltd Transmucosal Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 82. Nemaura Pharma Ltd Transmucosal Drug Delivery Product Portfolio Table 83. Nemaura Pharma Ltd Recent Development Table 84. MedPharm LTD Company Information Table 85. MedPharm LTD Business Overview Table 86. MedPharm LTD Transmucosal Drug Delivery Revenue (US$ Million) and Gross Margin (2021-2026) Table 87. MedPharm LTD Transmucosal Drug Delivery Product Portfolio Table 88. MedPharm LTD Recent Development Table 89. Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Company Information Table 90. Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Business Overview Table 91. Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 92. Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Transmucosal Drug Delivery Product Portfolio Table 93. Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Recent Development Table 94. Inovio Pharmaceuticals, Inc. Company Information Table 95. Inovio Pharmaceuticals, Inc. Business Overview Table 96. Inovio Pharmaceuticals, Inc. Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 97. Inovio Pharmaceuticals, Inc. Transmucosal Drug Delivery Product Portfolio Table 98. Inovio Pharmaceuticals, Inc. Recent Development Table 99. Generex Biotechnology Corporation Company Information Table 100. Generex Biotechnology Corporation Business Overview Table 101. Generex Biotechnology Corporation Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 102. Generex Biotechnology Corporation Transmucosal Drug Delivery Product Portfolio Table 103. Generex Biotechnology Corporation Recent Development Table 104. DURECT Corporation Company Information Table 105. DURECT Corporation Business Overview Table 106. DURECT Corporation Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 107. DURECT Corporation Transmucosal Drug Delivery Product Portfolio Table 108. DURECT Corporation Recent Development Table 109. Corium International, Inc Company Information Table 110. Corium International, Inc Business Overview Table 111. Corium International, Inc Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 112. Corium International, Inc Transmucosal Drug Delivery Product Portfolio Table 113. Corium International, Inc Recent Development Table 114. Aveva Drug Delivery Systems Company Information Table 115. Aveva Drug Delivery Systems Business Overview Table 116. Aveva Drug Delivery Systems Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 117. Aveva Drug Delivery Systems Transmucosal Drug Delivery Product Portfolio Table 118. Aveva Drug Delivery Systems Recent Development Table 119. Apricus BioSciences, Inc Company Information Table 120. Apricus BioSciences, Inc Business Overview Table 121. Apricus BioSciences, Inc Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 122. Apricus BioSciences, Inc Transmucosal Drug Delivery Product Portfolio Table 123. Apricus BioSciences, Inc Recent Development Table 124. Antares Pharma, Inc. Company Information Table 125. Antares Pharma, Inc. Business Overview Table 126. Antares Pharma, Inc. Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 127. Antares Pharma, Inc. Transmucosal Drug Delivery Product Portfolio Table 128. Antares Pharma, Inc. Recent Development Table 129. ALZA Corporation Company Information Table 130. ALZA Corporation Business Overview Table 131. ALZA Corporation Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 132. ALZA Corporation Transmucosal Drug Delivery Product Portfolio Table 133. ALZA Corporation Recent Development Table 134. Acrux Limited Company Information Table 135. Acrux Limited Business Overview Table 136. Acrux Limited Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 137. Acrux Limited Transmucosal Drug Delivery Product Portfolio Table 138. Acrux Limited Recent Development Table 139. 3M Pharmaceuticals Company Information Table 140. 3M Pharmaceuticals Business Overview Table 141. 3M Pharmaceuticals Transmucosal Drug Delivery Sales (k units), Value (US$ Million), Price (US$/unit) and Gross Margin (2021-2026) Table 142. 3M Pharmaceuticals Transmucosal Drug Delivery Product Portfolio Table 143. 3M Pharmaceuticals Recent Development Table 144. Research Programs/Design for This Report Table 145. Authors List of This Report Table 146. Secondary Sources Table 147. Primary Sources List of Figures Figure 1. Transmucosal Drug Delivery Product Image Figure 2. Global Transmucosal Drug Delivery Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Transmucosal Drug Delivery Market Size (2021-2032) & (US$ Million) Figure 4. Global Transmucosal Drug Delivery Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. Passive Transdermal Drug Delivery Image Figure 8. Active Transdermal Drug Delivery Image Figure 9. Global Transmucosal Drug Delivery Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 10. Global Transmucosal Drug Delivery Sales Value Share 2021 VS 2025 VS 2032 Figure 11. Global Transmucosal Drug Delivery Sales Value Share by Type (2021-2032) Figure 12. Hospital Image Figure 13. Clinic Image Figure 14. Others Image Figure 15. Global Transmucosal Drug Delivery Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 16. Global Transmucosal Drug Delivery Sales Value Share 2021 VS 2025 VS 2032 Figure 17. Global Transmucosal Drug Delivery Sales Value Share by Application (2021-2032) Figure 18. Global Transmucosal Drug Delivery Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 19. Global Transmucosal Drug Delivery Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 20. North America Transmucosal Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 21. North America Transmucosal Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 22. Europe Transmucosal Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 23. Europe Transmucosal Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 24. Asia-Pacific Transmucosal Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 25. Asia-Pacific Transmucosal Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 26. South America Transmucosal Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 27. South America Transmucosal Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 28. Middle East & Africa Transmucosal Drug Delivery Sales Value (2021-2032) & (US$ Million) Figure 29. Middle East & Africa Transmucosal Drug Delivery Sales Value Share by Country (%), 2025 VS 2032 Figure 30. USA Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 31. USA Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 32. USA Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 33. Canada Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 34. Canada Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 35. Canada Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 36. Mexico Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 37. Mexico Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 38. Mexico Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 39. Germany Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 40. Germany Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 41. Germany Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 42. France Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 43. France Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 44. France Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 45. U.K. Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 46. U.K. Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 47. U.K. Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 48. Italy Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 49. Italy Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 50. Italy Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 51. Spain Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 52. Spain Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 53. Spain Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 54. Russia Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 55. Russia Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 56. Russia Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 57. Netherlands Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 58. Netherlands Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 59. Netherlands Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 60. Nordic Countries Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 61. Nordic Countries Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 62. Nordic Countries Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 63. China Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 64. China Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 65. China Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 66. Japan Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 67. Japan Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 68. Japan Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 69. South Korea Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 70. South Korea Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 71. South Korea Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 72. India Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 73. India Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 74. India Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 75. Australia Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 76. Australia Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 77. Australia Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 78. Southeast Asia Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 79. Southeast Asia Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 80. Southeast Asia Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 81. Brazil Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 82. Brazil Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 83. Brazil Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 84. Argentina Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 85. Argentina Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 86. Argentina Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 87. Chile Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 88. Chile Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 89. Chile Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 90. Colombia Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 91. Colombia Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 92. Colombia Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 93. Peru Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 94. Peru Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 95. Peru Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 96. Saudi Arabia Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 97. Saudi Arabia Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 98. Saudi Arabia Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 99. Israel Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 100. Israel Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 101. Israel Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 102. UAE Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 103. UAE Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 104. UAE Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 105. Turkey Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 106. Turkey Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 107. Turkey Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 108. Iran Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 109. Iran Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 110. Iran Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 111. Egypt Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 112. Egypt Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032 & (%) Figure 113. Egypt Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032 & (%) Figure 114. Years Considered Figure 115. Research Process Figure 116. Key Executives Interviewed

Scope & coverage.

Types
  • Passive Transdermal Drug Delivery
  • Active Transdermal Drug Delivery
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • TEVA Pharmaceutical Industries Ltd.
  • Mylan, Inc.
  • Zosano Pharma
  • tesa Labtec GmbH
  • Tapemark
  • Pantec Biosolutions AG
  • Noven Pharmaceuticals, Inc.
  • Nitto Denko Corporation
  • Nemaura Pharma Ltd
  • MedPharm LTD
  • Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)
  • Inovio Pharmaceuticals, Inc.
  • Generex Biotechnology Corporation
  • DURECT Corporation
  • Corium International, Inc
  • Aveva Drug Delivery Systems
  • Apricus BioSciences, Inc
  • Antares Pharma, Inc.
  • ALZA Corporation
  • Acrux Limited
  • 3M Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Transmucosal Drug Delivery Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Transmucosal Drug Delivery Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 Transmucosal Drug Delivery Market Dynamics
  1. 2.1 Transmucosal Drug Delivery Industry Trends
  2. 2.2 Transmucosal Drug Delivery Industry Drivers
  3. 2.3 Transmucosal Drug Delivery Industry Opportunities and Challenges
  4. 2.4 Transmucosal Drug Delivery Industry Restraints
3 Transmucosal Drug Delivery Market by Company
  1. 3.1 Global Transmucosal Drug Delivery Company Revenue Ranking in 2025
  2. 3.2 Global Transmucosal Drug Delivery Revenue by Company (2021-2026)
  3. 3.3 Global Transmucosal Drug Delivery Company Ranking (2024-2026)
  4. 3.4 Global Transmucosal Drug Delivery Company Manufacturing Base and Headquarters
  5. 3.5 Global Transmucosal Drug Delivery Company Product Type and Application
  6. 3.6 Global Transmucosal Drug Delivery Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global Transmucosal Drug Delivery Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 Transmucosal Drug Delivery Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 Transmucosal Drug Delivery Market by Type
  1. 4.1 Transmucosal Drug Delivery Type Introduction
  2. 4.1.1 Passive Transdermal Drug Delivery
  3. 4.1.2 Active Transdermal Drug Delivery
  4. 4.2 Global Transmucosal Drug Delivery Sales Value by Type
  5. 4.2.1 Global Transmucosal Drug Delivery Sales Value by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Transmucosal Drug Delivery Sales Value by Type (2021-2032)
  7. 4.2.3 Global Transmucosal Drug Delivery Sales Value Share by Type (2021-2032)
5 Transmucosal Drug Delivery Market by Application
  1. 5.1 Transmucosal Drug Delivery Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global Transmucosal Drug Delivery Sales Value by Application
  6. 5.2.1 Global Transmucosal Drug Delivery Sales Value by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Transmucosal Drug Delivery Sales Value by Application (2021-2032)
  8. 5.2.3 Global Transmucosal Drug Delivery Sales Value Share by Application (2021-2032)
6 Transmucosal Drug Delivery Regional Value Analysis
  1. 6.1 Global Transmucosal Drug Delivery Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Transmucosal Drug Delivery Sales Value by Region (2021-2032)
  3. 6.2.1 Global Transmucosal Drug Delivery Sales Value by Region: 2021-2026
  4. 6.2.2 Global Transmucosal Drug Delivery Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Transmucosal Drug Delivery Sales Value (2021-2032)
  7. 6.3.2 North America Transmucosal Drug Delivery Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe Transmucosal Drug Delivery Sales Value (2021-2032)
  10. 6.4.2 Europe Transmucosal Drug Delivery Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific Transmucosal Drug Delivery Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific Transmucosal Drug Delivery Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America Transmucosal Drug Delivery Sales Value (2021-2032)
  16. 6.6.2 South America Transmucosal Drug Delivery Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa Transmucosal Drug Delivery Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa Transmucosal Drug Delivery Sales Value Share by Country, 2025 VS 2032
7 Transmucosal Drug Delivery Country-level Value Analysis
  1. 7.1 Global Transmucosal Drug Delivery Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Transmucosal Drug Delivery Sales Value by Country (2021-2032)
  3. 7.2.1 Global Transmucosal Drug Delivery Sales Value by Country (2021-2026)
  4. 7.2.2 Global Transmucosal Drug Delivery Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt Transmucosal Drug Delivery Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt Transmucosal Drug Delivery Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt Transmucosal Drug Delivery Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 TEVA Pharmaceutical Industries Ltd.
  2. 8.1.1 TEVA Pharmaceutical Industries Ltd. Company Information
  3. 8.1.2 TEVA Pharmaceutical Industries Ltd. Business Overview
  4. 8.1.3 TEVA Pharmaceutical Industries Ltd. Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  5. 8.1.4 TEVA Pharmaceutical Industries Ltd. Transmucosal Drug Delivery Product Portfolio
  6. 8.1.5 TEVA Pharmaceutical Industries Ltd. Recent Developments
  7. 8.2 Mylan, Inc.
  8. 8.2.1 Mylan, Inc. Company Information
  9. 8.2.2 Mylan, Inc. Business Overview
  10. 8.2.3 Mylan, Inc. Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Mylan, Inc. Transmucosal Drug Delivery Product Portfolio
  12. 8.2.5 Mylan, Inc. Recent Developments
  13. 8.3 Zosano Pharma
  14. 8.3.1 Zosano Pharma Company Information
  15. 8.3.2 Zosano Pharma Business Overview
  16. 8.3.3 Zosano Pharma Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Zosano Pharma Transmucosal Drug Delivery Product Portfolio
  18. 8.3.5 Zosano Pharma Recent Developments
  19. 8.4 tesa Labtec GmbH
  20. 8.4.1 tesa Labtec GmbH Company Information
  21. 8.4.2 tesa Labtec GmbH Business Overview
  22. 8.4.3 tesa Labtec GmbH Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  23. 8.4.4 tesa Labtec GmbH Transmucosal Drug Delivery Product Portfolio
  24. 8.4.5 tesa Labtec GmbH Recent Developments
  25. 8.5 Tapemark
  26. 8.5.1 Tapemark Company Information
  27. 8.5.2 Tapemark Business Overview
  28. 8.5.3 Tapemark Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Tapemark Transmucosal Drug Delivery Product Portfolio
  30. 8.5.5 Tapemark Recent Developments
  31. 8.6 Pantec Biosolutions AG
  32. 8.6.1 Pantec Biosolutions AG Company Information
  33. 8.6.2 Pantec Biosolutions AG Business Overview
  34. 8.6.3 Pantec Biosolutions AG Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Pantec Biosolutions AG Transmucosal Drug Delivery Product Portfolio
  36. 8.6.5 Pantec Biosolutions AG Recent Developments
  37. 8.7 Noven Pharmaceuticals, Inc.
  38. 8.7.1 Noven Pharmaceuticals, Inc. Company Information
  39. 8.7.2 Noven Pharmaceuticals, Inc. Business Overview
  40. 8.7.3 Noven Pharmaceuticals, Inc. Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Noven Pharmaceuticals, Inc. Transmucosal Drug Delivery Product Portfolio
  42. 8.7.5 Noven Pharmaceuticals, Inc. Recent Developments
  43. 8.8 Nitto Denko Corporation
  44. 8.8.1 Nitto Denko Corporation Company Information
  45. 8.8.2 Nitto Denko Corporation Business Overview
  46. 8.8.3 Nitto Denko Corporation Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Nitto Denko Corporation Transmucosal Drug Delivery Product Portfolio
  48. 8.8.5 Nitto Denko Corporation Recent Developments
  49. 8.9 Nemaura Pharma Ltd
  50. 8.9.1 Nemaura Pharma Ltd Company Information
  51. 8.9.2 Nemaura Pharma Ltd Business Overview
  52. 8.9.3 Nemaura Pharma Ltd Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Nemaura Pharma Ltd Transmucosal Drug Delivery Product Portfolio
  54. 8.9.5 Nemaura Pharma Ltd Recent Developments
  55. 8.10 MedPharm LTD
  56. 8.10.1 MedPharm LTD Company Information
  57. 8.10.2 MedPharm LTD Business Overview
  58. 8.10.3 MedPharm LTD Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  59. 8.10.4 MedPharm LTD Transmucosal Drug Delivery Product Portfolio
  60. 8.10.5 MedPharm LTD Recent Developments
  61. 8.11 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG)
  62. 8.11.1 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Company Information
  63. 8.11.2 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Business Overview
  64. 8.11.3 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Transmucosal Drug Delivery Product Portfolio
  66. 8.11.5 Lohmann Therapy-Systems Corp (LTS Lohmann Therapie Systeme AG) Recent Developments
  67. 8.12 Inovio Pharmaceuticals, Inc.
  68. 8.12.1 Inovio Pharmaceuticals, Inc. Company Information
  69. 8.12.2 Inovio Pharmaceuticals, Inc. Business Overview
  70. 8.12.3 Inovio Pharmaceuticals, Inc. Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Inovio Pharmaceuticals, Inc. Transmucosal Drug Delivery Product Portfolio
  72. 8.12.5 Inovio Pharmaceuticals, Inc. Recent Developments
  73. 8.13 Generex Biotechnology Corporation
  74. 8.13.1 Generex Biotechnology Corporation Company Information
  75. 8.13.2 Generex Biotechnology Corporation Business Overview
  76. 8.13.3 Generex Biotechnology Corporation Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Generex Biotechnology Corporation Transmucosal Drug Delivery Product Portfolio
  78. 8.13.5 Generex Biotechnology Corporation Recent Developments
  79. 8.14 DURECT Corporation
  80. 8.14.1 DURECT Corporation Company Information
  81. 8.14.2 DURECT Corporation Business Overview
  82. 8.14.3 DURECT Corporation Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  83. 8.14.4 DURECT Corporation Transmucosal Drug Delivery Product Portfolio
  84. 8.14.5 DURECT Corporation Recent Developments
  85. 8.15 Corium International, Inc
  86. 8.15.1 Corium International, Inc Company Information
  87. 8.15.2 Corium International, Inc Business Overview
  88. 8.15.3 Corium International, Inc Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Corium International, Inc Transmucosal Drug Delivery Product Portfolio
  90. 8.15.5 Corium International, Inc Recent Developments
  91. 8.16 Aveva Drug Delivery Systems
  92. 8.16.1 Aveva Drug Delivery Systems Company Information
  93. 8.16.2 Aveva Drug Delivery Systems Business Overview
  94. 8.16.3 Aveva Drug Delivery Systems Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  95. 8.16.4 Aveva Drug Delivery Systems Transmucosal Drug Delivery Product Portfolio
  96. 8.16.5 Aveva Drug Delivery Systems Recent Developments
  97. 8.17 Apricus BioSciences, Inc
  98. 8.17.1 Apricus BioSciences, Inc Company Information
  99. 8.17.2 Apricus BioSciences, Inc Business Overview
  100. 8.17.3 Apricus BioSciences, Inc Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  101. 8.17.4 Apricus BioSciences, Inc Transmucosal Drug Delivery Product Portfolio
  102. 8.17.5 Apricus BioSciences, Inc Recent Developments
  103. 8.18 Antares Pharma, Inc.
  104. 8.18.1 Antares Pharma, Inc. Company Information
  105. 8.18.2 Antares Pharma, Inc. Business Overview
  106. 8.18.3 Antares Pharma, Inc. Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  107. 8.18.4 Antares Pharma, Inc. Transmucosal Drug Delivery Product Portfolio
  108. 8.18.5 Antares Pharma, Inc. Recent Developments
  109. 8.19 ALZA Corporation
  110. 8.19.1 ALZA Corporation Company Information
  111. 8.19.2 ALZA Corporation Business Overview
  112. 8.19.3 ALZA Corporation Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  113. 8.19.4 ALZA Corporation Transmucosal Drug Delivery Product Portfolio
  114. 8.19.5 ALZA Corporation Recent Developments
  115. 8.20 Acrux Limited
  116. 8.20.1 Acrux Limited Company Information
  117. 8.20.2 Acrux Limited Business Overview
  118. 8.20.3 Acrux Limited Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  119. 8.20.4 Acrux Limited Transmucosal Drug Delivery Product Portfolio
  120. 8.20.5 Acrux Limited Recent Developments
  121. 8.21 3M Pharmaceuticals
  122. 8.21.1 3M Pharmaceuticals Company Information
  123. 8.21.2 3M Pharmaceuticals Business Overview
  124. 8.21.3 3M Pharmaceuticals Transmucosal Drug Delivery Revenue and Gross Margin (2021-2026)
  125. 8.21.4 3M Pharmaceuticals Transmucosal Drug Delivery Product Portfolio
  126. 8.21.5 3M Pharmaceuticals Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst